TORNTPHARM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.4
| Stock Code | TORNTPHARM | Market Cap | 1,41,643 Cr. | Current Price | 4,185 ₹ | High / Low | 4,483 ₹ |
| Stock P/E | 63.4 | Book Value | 250 ₹ | Dividend Yield | 0.76 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 4,162 ₹ | DMA 200 | 3,871 ₹ |
| Chg in FII Hold | 0.05 % | Chg in DII Hold | -0.09 % | PAT Qtr | 584 Cr. | PAT Prev Qtr | 606 Cr. |
| RSI | 50.8 | MACD | -4.12 | Volume | 2,99,928 | Avg Vol 1Wk | 3,06,517 |
| Low price | 3,101 ₹ | High price | 4,483 ₹ | PEG Ratio | 2.61 | Debt to equity | 0.25 |
| 52w Index | 78.4 % | Qtr Profit Var | 20.4 % | EPS | 65.0 ₹ | Industry PE | 30.1 |
📈 Chart & Trend: TORNTPHARM is trading slightly above its 50 DMA (4,162 ₹) but below the recent high of 4,483 ₹, showing short-term resilience but medium-term resistance. RSI at 50.8 indicates neutral momentum, while MACD at -4.12 reflects bearish crossover. Bollinger Bands are moderately tight, suggesting consolidation with downside risk.
🔑 Momentum Signals: Current price (4,185 ₹) is holding near support at 4,160–4,170 ₹. Resistance levels are seen at 4,220 ₹ and 4,260 ₹. Volume (2.99L) is slightly below the 1-week average (3.06L), showing reduced participation and limited conviction.
🎯 Entry Zone: 4,160–4,170 ₹ near support.
💰 Exit Zone: 4,220 ₹ (partial profit) and 4,260 ₹ (full exit).
📊 Trend Status: Consolidating with mild bearish bias.
Positive
- Strong ROCE (27.8%) and ROE (26.2%) highlight profitability.
- EPS at 65.0 ₹ supports valuation strength.
- Price trading above 50 DMA confirms short-term support.
- Quarterly profit variation +20.4% shows year-on-year improvement.
Limitation
- High P/E (63.4) vs industry PE (30.1) indicates overvaluation.
- MACD negative crossover signals weak momentum.
- Volume slightly below average, limiting breakout strength.
- Price still below recent highs, capping upside potential.
Company Negative News
- PAT declined sequentially (584 Cr. vs 606 Cr.).
- DII holdings reduced (-0.09%).
Company Positive News
- FII holdings increased (+0.05%), showing foreign investor confidence.
- Strong EPS and profitability metrics support long-term outlook.
Industry
- Industry PE at 30.1 suggests sector trading at moderate valuations compared to TORNTPHARM’s premium.
- Pharma sector remains resilient with steady demand but faces pricing pressures.
Conclusion
TORNTPHARM is consolidating with mild bearish bias, supported by neutral RSI and negative MACD. Entry near 4,160–4,170 ₹ is favorable for cautious trades with exits at 4,220–4,260 ₹. While fundamentals remain strong with high ROCE/ROE and EPS, stretched valuations and weak momentum limit conviction. Best suited for short-term swing trades with strict stop-loss discipline.